• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is BioArctic (OM:BIOA B) Fairly Valued Following Leqembi's First Private Clinic Use In Sweden?

    Simply Wall St·10/01/2026 07:15:57
    語音播報

    BioArctic (OM:BIOA B) moved further into real world Alzheimer’s treatment after announcing that Leqembi is now used at a private clinic in Sweden, with the first patient starting therapy.

    Against this backdrop, BioArctic’s 1-day share price return of 1.57% sits alongside a 7-day share price decline of 3.60% and a 90-day share price fall of 6.51%, while the 5-year total shareholder return of 100.93% points to a very different long-term story.

    Scan beyond BioArctic and see how other CNS and healthcare developers are positioned right now by reviewing our curated 617 high quality undiscovered gems in this space.

    Bulls point to BioArctic’s growing Alzheimer’s footprint and strong recent revenue and net income figures, while bears focus on reimbursement pushback and recent share price weakness. Which side does the current valuation support?

    Most Popular Narrative: 2% Undervalued

    Based on the most followed narrative, BioArctic’s fair value of SEK316.75 sits slightly above the last close at SEK310.40, which puts current pricing almost on top of that modelled estimate while still leaving a slim margin.

    The analysts have a consensus price target of SEK316.75 for BioArctic based on their expectations of its future earnings growth, profit margins and other risk factors.

    In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be SEK2.5 billion, earnings will come to SEK1.9 billion, and it would be trading on a PE ratio of 17.5x, assuming you use a discount rate of 5.3%.

    See why 19 investors see BioArctic as 2% undervalued.

    Result: Fair Value of SEK316.75 (UNDERVALUED)

    Still, concentration in Leqembi and any shift in payer support could quickly challenge the thesis that BioArctic’s current pricing only modestly lags fair value.

    Find out about the key risks to this BioArctic narrative.

    Another View on BioArctic’s Valuation

    Analyst narratives lean on earnings forecasts and fair value of SEK316.75, yet BioArctic’s P/S of 27.5x looks heavy compared with the Swedish Biotechs industry on 12.4x, peers at 7x, and a fair ratio of 15.1x. Is the market paying too much for today’s revenue base?

    For a closer look at how this valuation gap could narrow or widen over time, See what the numbers say about this price — find out in our valuation breakdown.

    OM:BIOA B P/S Ratio as at Oct 2026
    OM:BIOA B P/S Ratio as at Oct 2026

    Next Steps

    Mixed signals around BioArctic’s valuation and risk profile make this a good moment to check the numbers yourself and decide where you stand. To weigh both the concern and the upside that other investors see, take a close look at the 1 key reward and 1 important warning sign.

    Looking for more investment ideas beyond BioArctic?

    If BioArctic has your attention, do not stop here. Broaden your watchlist with other focused opportunities that fit different goals and risk levels.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.